Pharmacokinetics, absorption, and excretion of radiolabeled revexepride: a Phase I clinical trial using a microtracer and accelerator mass spectrometry-based approach-Reference-Cited by-同舟云学术

Pharmacokinetics, absorption, and excretion of radiolabeled revexepride: a Phase I clinical trial using a microtracer and accelerator mass spectrometry-based approach

Published:2016-09 Issue: Volume:Volume 10 Page:3125-3132
ISSN:1177-8881
Container-title:Drug Design, Development and Therapy
language:en
Short-container-title:DDDT

Author:

Flach Stephen,Croft Marie,Ding Jie,Budhram Ron,Pankratz Todd,Pennick Mike,Scarfe Graeme,Troy Steven,Getsy Jay

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmaceutical Science,Pharmacology

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Absorption, Metabolism, and Excretion of [¹⁴C]‐Labeled Anaprazole: A New Proton Pump Inhibitor, After a Single Oral Administration in Healthy Chinese Male Subjects;Clinical Pharmacology in Drug Development;2024-08-05

2. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans;Drug Metabolism and Disposition;2023-01-13

3. Design, conduct, and interpretation of human mass balance studies and strategies for assessing metabolites-in-safety testing (MIST) in drug development;Overcoming Obstacles in Drug Discovery and Development;2023

4. Advancements in practical and scientific bioanalytical approaches to metabolism studies in drug development;Bioanalysis;2021-06

5. Metabolism of the Dual Orexin Receptor Antagonist ACT-541468, Based on Microtracer/ Accelerator Mass Spectrometry;Current Drug Metabolism;2019-06-11